221 related articles for article (PubMed ID: 18647411)
1. Differentiation of two types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis.
Jin P; Wang E; Ren J; Childs R; Shin JW; Khuu H; Marincola FM; Stroncek DF
J Transl Med; 2008 Jul; 6():39. PubMed ID: 18647411
[TBL] [Abstract][Full Text] [Related]
2. Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures.
Donahue RE; Jin P; Bonifacino AC; Metzger ME; Ren J; Wang E; Stroncek DF
Blood; 2009 Sep; 114(12):2530-41. PubMed ID: 19602709
[TBL] [Abstract][Full Text] [Related]
3. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor.
Bruns I; Steidl U; Fischer JC; Czibere A; Kobbe G; Raschke S; Singh R; Fenk R; Rosskopf M; Pechtel S; von Haeseler A; Wernet P; Tenen DG; Haas R; Kronenwett R
Haematologica; 2008 Mar; 93(3):347-55. PubMed ID: 18268278
[TBL] [Abstract][Full Text] [Related]
4. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates.
Larochelle A; Krouse A; Metzger M; Orlic D; Donahue RE; Fricker S; Bridger G; Dunbar CE; Hematti P
Blood; 2006 May; 107(9):3772-8. PubMed ID: 16439684
[TBL] [Abstract][Full Text] [Related]
5. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist.
Liles WC; Rodger E; Broxmeyer HE; Dehner C; Badel K; Calandra G; Christensen J; Wood B; Price TH; Dale DC
Transfusion; 2005 Mar; 45(3):295-300. PubMed ID: 15752146
[TBL] [Abstract][Full Text] [Related]
6. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
[TBL] [Abstract][Full Text] [Related]
7. CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients.
Varmavuo V; Mäntymaa P; Silvennoinen R; Nousiainen T; Kuittinen T; Jantunen E
Transfusion; 2013 May; 53(5):1024-32. PubMed ID: 22897584
[TBL] [Abstract][Full Text] [Related]
8. Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor.
Hess DA; Bonde J; Craft TP; Wirthlin L; Hohm S; Lahey R; Todt LM; Dipersio JF; Devine SM; Nolta JA
Biol Blood Marrow Transplant; 2007 Apr; 13(4):398-411. PubMed ID: 17382247
[TBL] [Abstract][Full Text] [Related]
9. Functional analysis of human hematopoietic repopulating cells mobilized with granulocyte colony-stimulating factor alone versus granulocyte colony-stimulating factor in combination with stem cell factor.
Hess DA; Levac KD; Karanu FN; Rosu-Myles M; White MJ; Gallacher L; Murdoch B; Keeney M; Ottowski P; Foley R; Chin-Yee I; Bhatia M
Blood; 2002 Aug; 100(3):869-78. PubMed ID: 12130497
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplantation: CD34+ cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells.
Choi D; Perrin M; Hoffmann S; Chang AE; Ratanatharathorn V; Uberti J; McDonagh KT; Mulé JJ
Clin Cancer Res; 1998 Nov; 4(11):2709-16. PubMed ID: 9829733
[TBL] [Abstract][Full Text] [Related]
11. Vigorous exercise mobilizes CD34+ hematopoietic stem cells to peripheral blood via the β
Agha NH; Baker FL; Kunz HE; Graff R; Azadan R; Dolan C; Laughlin MS; Hosing C; Markofski MM; Bond RA; Bollard CM; Simpson RJ
Brain Behav Immun; 2018 Feb; 68():66-75. PubMed ID: 29017969
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer.
Burns LJ; Weisdorf DJ; DeFor TE; Repka TL; Ogle KM; Hummer C; Miller JS
Exp Hematol; 2000 Jan; 28(1):96-103. PubMed ID: 10658681
[TBL] [Abstract][Full Text] [Related]
13. Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation.
Gattillo S; Marktel S; Rizzo L; Malato S; Malabarba L; Coppola M; Assanelli A; Milani R; De Freitas T; Corti C; Bellio L; Ciceri F
Transfusion; 2015 Aug; 55(8):1993-2000. PubMed ID: 25721167
[TBL] [Abstract][Full Text] [Related]
14. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
15. The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics.
Fruehauf S; Seeger T; Maier P; Li L; Weinhardt S; Laufs S; Wagner W; Eckstein V; Bridger G; Calandra G; Wenz F; Zeller WJ; Goldschmidt H; Ho AD
Exp Hematol; 2006 Aug; 34(8):1052-9. PubMed ID: 16863911
[TBL] [Abstract][Full Text] [Related]
16. Combined G-CSF and Plerixafor enhance hematopoietic recovery of CD34
Arcangeli ML; Brault P; Bourhis JH; Kuhnowskie F; Henry E; Barroca V; Koscielny S; Pflumio F; Amsellem S
Exp Hematol; 2020 Jun; 86():15-20.e2. PubMed ID: 32450206
[TBL] [Abstract][Full Text] [Related]
17. Identification and isolation from either adult human bone marrow or G-CSF-mobilized peripheral blood of CD34(+)/CD133(+)/CXCR4(+)/ Lin(-)CD45(-) cells, featuring morphological, molecular, and phenotypic characteristics of very small embryonic-like (VSEL) stem cells.
Sovalat H; Scrofani M; Eidenschenk A; Pasquet S; Rimelen V; Hénon P
Exp Hematol; 2011 Apr; 39(4):495-505. PubMed ID: 21238532
[TBL] [Abstract][Full Text] [Related]
18. FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation.
Brave M; Farrell A; Ching Lin S; Ocheltree T; Pope Miksinski S; Lee SL; Saber H; Fourie J; Tornoe C; Booth B; Yuan W; He K; Justice R; Pazdur R
Oncology; 2010; 78(3-4):282-8. PubMed ID: 20530974
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic stem cells and liver regeneration: differentially acting hematopoietic stem cell mobilization agents reverse induced chronic liver injury.
Tsolaki E; Athanasiou E; Gounari E; Zogas N; Siotou E; Yiangou M; Anagnostopoulos A; Yannaki E
Blood Cells Mol Dis; 2014 Sep; 53(3):124-32. PubMed ID: 24923531
[TBL] [Abstract][Full Text] [Related]
20. CD133+ cell content does not influence recovery time after hematopoietic stem cell transplantation.
Jaime-Pérez JC; Guillermo-Villanueva VA; Méndez-Ramírez N; Chapa-Rodríguez A; Gutiérrez-Aguirre H; Gómez-Almaguer D
Transfusion; 2009 Nov; 49(11):2390-4. PubMed ID: 19903294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
